Raymond March Archive

Raymond J. March is a Research Fellow at the Independent Institute and Assistant Professor of Economics at San José State University. His research examines the public and private provision and governance of healthcare in the United States, particularly in pharmaceutical markets.

Curing Diseases Is Sustainable, Government in Healthcare Is Not



While Americans have every reason to be concerned about their healthcare, the belief that private medical companies will not develop and produce products that cure various conditions is unwarranted.

FDA Issues First Mandatory Recall for Contaminated Food



The U.S. Food and Drug Administration recently issued a mandatory recall for Triangle Pharmanaturals, a Las Vegas-based herbal supplements company.

FDA Restricts Sale of Contraceptive Device



The FDA released an order indicating its intent to restrict the sale of the contraceptive device Essure, the only FDA-approved nonsurgical permanent birth control method.

FDA Cracks Down on Online Eye-Exam Company



This past October, the Food and Drug Administration issued a warning letter to Opternative, a company specializing in providing online eye-exams.

The FDA Plans to Regulate Nicotine in Cigarettes



How likely are smokers to quit or cut back once nicotine levels decrease?

Politics Is Costing Lives by Delaying Right-to-Try Legislation



Upon deeper inspection, it seems the conventional arguments against right-to-try come up short.

Misdiagnosing Right-to-try Laws



Right-to-try laws only apply to terminally ill patients who have exhausted all other options.

Markets Provide Care for an Aging Population



Technological advancements continue to provide cheaper and more effective solutions for healthcare’s most difficult problems.

Medical Apps: Improving Healthcare on a Global Scale



Health apps use smartphone technology to provide medical assistance or access to medical professionals.

FDA Greenlights Testing ‘Ecstasy’ for PTSD Therapy



MDMA, more commonly called “ecstasy” or “Molly,” is an illicit substance often taken to induce euphoria. The Controlled Substance Act considers MDMA a Schedule 1 controlled substance, which has no known medicinal benefits and a high likelihood of abuse. Penalties for using or distributing MDMA are considerably high even for a Schedule 1 substance....
Read More »

  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org